OncoMatch/Clinical Trials/NCT05957016
Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer
Is NCT05957016 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for rectal cancer.
To increase the efficacy of neoadjuvant PD-1/PD-1 checkpoint inhibitor in local advanced rectal cancer (LARC), we propose preoperative arterial infusion of Tirellizumab and oxaliplatin followed by tumor artery embolization with concurrent chemoradiotherapy as neoadjuvant regimen for LARC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage T3/4NANYM0, T1-2N+M0 (TNM)
Local advanced Rectal cancer: stage T3/4NanyM0 or T1-2N+M0
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
WBC ≥ 4,000/mm3; Neutrophil count ≥ 1,500/mm3; Hemoglobin ≥ 10 g/dL; Platelet count ≥ 100,000/mm3
Kidney function
Serum creatinine ≤1.5x ULN or creatinine clearance ≥60 ml/min
Liver function
Total bilirubin ≤ 1.5x ULN; AST & ALT ≤ 1.5x ULN
White blood cell count ≥ 4,000/mm3. Neutrophil count ≥ 1,500/mm3. Hemoglobin ≥ 10 g/dL. Platelet count ≥ 100,000/mm3. Total bilirubin ≤ 1.5x ULN. AST & ALT ≤ 1.5x ULN. Serum creatinine ≤1.5x ULN or creatinine clearance ≥60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify